By staff writers
March 1, 2017

GE Healthcare is launching its new Clariscan (gadoteric acid) MRI contrast agent at this week's ECR 2017 meeting in Vienna.

The gadolinium-based contrast agent (GBCA) is designed to visualize abnormalities in the brain, spine, and associated tissues. The macrocyclic and ionic contrast agent will be available in a range of doses in vials and prefilled syringes, and it joins the company's linear GBCA Omniscan, which has been used for MR imaging for more than 25 years.

Thus far, Clariscan has received approval for marketing and distribution in Norway. GE plans to introduce the new contrast agent to the rest of Europe this year.

GE to modernize five Kuwait hospitals
GE Healthcare is partnering with Advanced Technology Co. (ATC) to bring advanced diagnostic imaging and digital technology to five new Ministry of Health...
GE places miniature neonatal MRI prototype in U.K.
GE Healthcare has installed a prototype of a miniature MRI system in the neonatal unit at the Jessop Wing Maternity Hospital in Sheffield, U.K.
GE pays tribute to Bucharest site
GE Healthcare has designated the Affidea Center in Bucharest's Fundeni Clinical Institute, Romania, as a Center of Excellence in Oncology and a European...
GE purchases expanded rights to Rapiscan stress agent
GE Healthcare's Life Sciences unit has purchased exclusive rights to produce and sell the Rapiscan pharmacological stress agent in territories outside...
BIR, GE partner on radiation safety travel award
The British Institute of Radiology (BIR) and GE Healthcare have joined forces to create a radiation safety travel award.

Copyright © 2017

Last Updated np 3/1/2017 1:02:33 PM